SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending as the community anticipates news, especially regarding potential pharmaceutical contracts and the closing of the pension transfer. Discussions center on Kodak's transformation beyond its legacy business, with optimism around its pharmaceutical and battery ventures. Some traders are looking at its potential as the next meme stock.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending amid community excitement over its recent price surge and increased staking activity, with many drawing comparisons to ZCash's historical run. The discussion centers around ICP's unique technology, particularly its "full-stack on-chain" model and potential to disrupt traditional internet infrastructure, as well as speculation on short-term price targets.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETR is trending due to community discussion around its potential for a short squeeze and future growth, fueled by AI integration in mortgage lending. The stock's volatility and a relatively low float are key talking points, with some comparing it to other high-flying stocks. Bullish sentiment is driven by potential rate cuts and the company's AI platform.

Ethereum Classic

Ethereum Classic ($ETC) is trending amid discussions about its potential as a cheaper alternative to Ethereum and renewed interest in Proof-of-Work coins, with some community members anticipating a significant price increase and comparing it to past bull runs. The community is actively debating its performance relative to Ethereum, with some suggesting it's undervalued and poised for a breakout, while others remain skeptical about its long-term potential.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

MRK is trending as investors discuss its pipeline potential, particularly in oncology, and potential acquisitions to offset Keytruda's future patent expiration. Community members are weighing the stock's valuation and recent performance against upcoming earnings and potential catalysts, such as new drug approvals. Discussions also include potential mergers with companies like MRNA and Iovance Biotherapeutics (IOVA).

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is trending amid discussions about its utility as a decentralized storage solution and its potential role in AI-related infrastructure, with some community members comparing it to Amazon AWS. Speculation is rising about a potential breakout, with some users pointing to specific resistance levels and others anticipating a broader altcoin season. The community is actively debating price targets and whether FIL can reclaim its all-time highs.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions around political events, including grand jury subpoenas and the government shutdown. Community chatter revolves around political affiliations, economic concerns, and the company's financial performance. Investors are closely watching for potential trading opportunities based on technical signals and news catalysts.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending as investors discuss whether the stock is oversold after a recent drop following earnings, with some citing an insider buy as a positive signal. Community members are debating the company's valuation relative to peers and speculating on a potential turnaround. Upcoming investor conferences and a Nasdaq listing are also key points of interest for traders.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSSI is trending due to its recent recognition as Forbes' #1 Most Successful Small-Cap Company and anticipation surrounding the upcoming Q3 earnings report. Community members are speculating on revenue figures, the potential for a merger with Dell, and the impact of new facilities and partnerships on the company's growth. Bullish sentiment is fueled by the increasing demand for AI data centers and TSSI's strategic positioning in the sector.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors assess the implications of its recent earnings report and a new partnership with Palantir, with community members weighing in on the company's long-term prospects in the AI infrastructure space.  Discussions revolve around the significance of new fiber contracts and the potential for revenue growth, as well as the company's debt and overall valuation. Some traders are taking profits, while others see the dip as a buying opportunity, focusing on the potential for long-term gains amid a telecom sector turnaround.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."read more...

Pfizer Sweetens Offer For Metsera To $86.25/shr Amid Escalating Bidding War With Novo Nordisk

(RTTNews) - Metsera Inc. (MTSR) announced that it has entered into an amended merger agreement with Pfizer, under which Pfizer will acquire Metsera for up to $86.25 per share. The deal includes...

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's...

Metsera (NASDAQ:MTSR) Trading Up 10.6% - Still a Buy?

Metsera (NASDAQ:MTSR) Trading 10.6% Higher - Here's What Happened...

Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call

Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.

Investors Purchase High Volume of Put Options on Metsera (NASDAQ:MTSR)

Metsera Inc. (NASDAQ:MTSR - Get Free Report) was the recipient of unusually large options trading on Thursday. Stock traders purchased 2,401 put options on the company. This represents an increase of...

Tesla Investors Approve Musk Pay Package, Comcast's Sky in Talks to Buy ITV  The Opening Trade 11/7

Tesla shareholders approved a potential $1 trillion compensation package for Chief Executive Officer Elon Musk, the largest payout ever awarded to a corporate leader. Musk would have to meet certain...

<ul class="summary-bullets"><li>The details of the new bid could not be immediately ascertained, FT said.</li><li>Pfizer now has two days to match Novo’s bid or let its agreed-upon deal with Metsera fall through, the report stated.&nbsp;</li><li>Pfizer reportedly matched Novo’s last offer late on Wednesday, prompting Novo’s new bid.<br>&nbsp;</li></ul><p>Danish drugmaker Novo Nordisk has reportedly sweetened its bid further for obesity drug maker Metsera amid a rising bidding war with Pfizer.</p><p>The Financial Times<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/52216b29-9f22-4338-85a7-eacfc33103a1"> reported</a> on Thursday, citing people familiar with the matter, that Novo raised its bid after Pfizer matched its last offer, valuing the company at up to $10 billion, late on Wednesday.</p><p>The details of the new bid could not be immediately ascertained, FT said. Pfizer now has two days to match Novo’s bid or let its agreed-upon deal with Metsera fall through, the report stated.&nbsp;</p><h2 class="st-heading-2">Start Of The Bidding War</h2><p>Novo Nordisk first announced last week that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September. Metsera determined that Novo’s bid was superior and gave Pfizer a certain number of days to negotiate the terms of their agreement. &nbsp;</p><p>On Monday, Metsera said that it has received revised bids from both Pfizer and Novo, valuing the company at up to $8.1 billion and $10 billion, respectively. Pfizer reportedly matched Novo’s offer late on Wednesday, prompting Novo’s new bid.</p><p>Pfizer had requested a temporary restraining order from the Delaware Chancery Court last week to prevent Metsera from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk. However, the court denied the request on Wednesday. Pfizer, however, said that it intends to pursue further litigation and expressed confidence in the merit of claims that Metsera has acted in breach of its contractual obligations. Metsera, on its side, dismissed Pfizer’s arguments as “nonsense.”</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p><a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> soared 14% at the time of writing. On Stocktwits, retail sentiment around MTSR stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.</p><p>MTSR stock has more than tripled this year.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/johnson-and-johnson-newly-acquired-antipsychotic-drug-approved-by-fda-for-major-depressive-disorder/cL2tuwZRERN">Johnson &amp; Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive Disorder</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further

According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through. 

Equity

<ul class="summary-bullets"><li>Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.</li><li>The court decision follows Metsera’s board reaffirming Novo’s revised $86.20-per-share offer as superior to Pfizer’s $8.1 billion counterproposal.</li><li>Pfizer vowed to continue its legal and antitrust challenges in Delaware federal court.</li></ul><p>Novo Nordisk’s U.S.-listed shares rose Wednesday, ending an 11-session losing streak, after a Delaware judge rejected Pfizer's request to block the Danish company’s $10 billion acquisition of obesity-drug startup Metsera Inc.</p><p>Delaware Chancery Judge Morgan Zurn said Pfizer’s objections didn’t warrant delaying the transaction and found no evidence Metsera’s board acted in bad faith when it labeled Novo’s offer “superior.” The ruling allows Novo to proceed with the deal, which topped Pfizer’s earlier $4.9 billion agreement announced in September, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-05/pfizer-loses-legal-bid-to-temporarily-block-novo-s-metsera-offer">report</a>.</p><h2 class="st-heading-2"><strong>Revised Offers Raise The Stakes</strong></h2><p>On Tuesday, Metsera said it received a revised offer from Novo valuing the company at up to $86.20 per share, or about $10 billion. The new proposal includes $62.20 per share in cash, up from $56.50 in the original bid, plus contingent value rights worth up to $24.00 per share if certain milestones are achieved.</p><p>Pfizer also revised its terms, increasing upfront consideration to $60 per share and trimming the contingent payout to $10 per share, valuing its bid at roughly $8.1 billion. Despite the adjustment, Metsera’s board reaffirmed Novo’s offer as superior and gave Pfizer two business days to counter before terminating its merger agreement.</p><h2 class="st-heading-2"><strong>Pfizer Vows To Keep Fighting</strong></h2><p>Pfizer said the ruling “fails to address the legal issues raised” and vowed to continue litigation in Delaware federal court, calling Novo’s bid “an unprecedented and illegal scheme to circumvent antitrust scrutiny.” The company alleges Novo’s move is designed to protect its dominance in the GLP-1 obesity-drug space by neutralizing a future competitor.</p><p>Novo countered that the court’s ruling validates its approach and serves shareholders’ best interests. Its offer, which includes both upfront and milestone-based payments, aims to bring Metsera’s experimental weight-loss portfolio, which is a potential rival to Ozempic and Wegovy, under its umbrella.</p><h2 class="st-heading-2"><strong>FTC Flags Premerger Concerns</strong></h2><p>The U.S. Federal Trade Commission warned that Novo’s offer could breach the Hart-Scott-Rodino Act if completed without premerger review. In a Nov. 4 letter, the FTC said the structure of Novo’s bid, which grants substantial upfront payments before regulatory approval, could reduce Metsera’s independence and incentive to pursue its drug pipeline.</p><h2 class="st-heading-2"><strong>Stocktwits Bulls Cheer, Bears Question The Deal</strong></h2><p>On Stocktwits, retail sentiment for Novo Nordisk was ‘extremely bullish’ amid a 159% jump in 24-hour message volume.</p><figure class="image"><img style="aspect-ratio:964/138;" src="https://news.stocktwits-cdn.com/nvo_ss_jpg_016bd02a5d.webp" alt="nvo ss.jpg" width="964" height="138"><figcaption>NVO sentiment and message volume as of November 5 | Source: Stocktwits</figcaption></figure><p>One user suggested that better days could be close, urging others to “hold strong.”</p><p><stembedurl>https://stocktwits.com/RunGoodStreakAlive/message/635121830</stembedurl></p><p>Another user, however, questioned whether Novo’s management understood investor sentiment, noting that Pfizer’s stock tends to rise each time it appears closer to reclaiming the Metsera deal, suggesting that shareholders aren’t convinced by Novo’s acquisition push.</p><p><stembedurl>https://stocktwits.com/GreenHawkz/message/635102183</stembedurl></p><p><a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> has declined 43% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal

Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.

<ul class="summary-bullets"><li>Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins.</li><li>Q3 sales rose 5% to 75 billion kroner, with Wegovy revenue up 18% but below expectations.</li><li>UBS said a potential $149-per-month U.S. pricing deal for obesity drugs could expand Medicare access but also weigh on Novo Nordisk’s global pricing power.</li></ul><p>Novo Nordisk’s new CEO, Mike Doustdar, cut the company’s profit forecast after slower Wegovy sales and rising competition in the obesity-drug market. The downgrade comes as the firm pursues a $10 billion bid for Metsera and, reportedly, nears a White House deal that could cap obesity-drug prices at $149 a month in exchange for Medicare coverage.</p><h2 class="st-heading-2"><strong>Earnings Review</strong></h2><p>Novo Nordisk, the maker of Wegovy and Ozempic, lowered its full-year guidance on Wednesday, signaling a rocky start for new CEO Mike Doustdar. The company now expects operating profit growth of 4%–7% in local currencies for 2025, down from an earlier 10%–16%, and sales growth of 8%–11%, below the previous 8%–14% range.</p><p>Doustdar attributed the cut to “lower growth expectations for our GLP-1 treatments,” adding that the company will accelerate efforts “to compete better in dynamic and increasingly competitive markets.”</p><p>Third-quarter sales rose 5 % to 75 billion Danish crowns ($11.7 billion). Wegovy sales climbed 18% to 20.35 billion Danish crowns, but missed expectations of 21.35 billion Danish crowns, as pricing pressure and rising competition from Eli Lilly’s Zepbound weighed on performance.</p><h2 class="st-heading-2"><strong>New CEO Faces Early Test</strong></h2><p>Doustdar, who took charge in August, faces one of Novo Nordisk’s toughest transitions in years. The company’s shares have dropped 43% in 2025, as pricing wars, U.S. policy headwinds, and management reshuffles have dented investor confidence in what was once Europe’s most valuable firm.</p><p>Novo Nordisk said its company-wide restructuring aims to streamline operations and reinvest for growth, with a renewed focus on obesity treatments.</p><h2 class="st-heading-2"><strong>Metsera Bid And Legal Battles</strong></h2><p>The Danish drugmaker’s revised $10 billion offer for U.S. obesity biotech Metsera has intensified its rivalry with Pfizer, which has filed two lawsuits alleging anticompetitive behavior.&nbsp;</p><p>Novo Nordisk dismissed the claims as “false and without merit.” Metsera said Novo’s latest proposal was “superior” to Pfizer’s, but the escalating bid raises investor concerns about cost discipline amid narrowing profit growth.</p><h2 class="st-heading-2"><strong>US Pricing Talks</strong></h2><p>Adding to the uncertainty, UBS said in a research note that Novo Nordisk and Eli Lilly’s supposed deal with the White House on obesity-drug pricing would cap prices at $149 per month for the lowest dose in exchange for Medicare coverage.</p><p>The investment bank described its stance as “mixed,” while Medicare inclusion could drive volume upside, the $149 price level represents a major discount versus global obesity-drug pricing. UBS, which rates Novo Nordisk shares as ‘Neutral’ with a 340 Danish crowns price target, said investors will watch whether the deal includes the Inflation Reduction Act’s Part D drug-price negotiation for semaglutide, and whether Novo has offered deep Wegovy discounts to preserve Ozempic pricing.</p><h2 class="st-heading-2"><strong>Investor Sentiment</strong></h2><p>Before the earnings announcement, Bourbon Capital&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/BourbonCap/status/1985846608320188641">noted in a post on X</a> that the company’s earnings yield and return on capital were considered "attractive," signaling confidence in Novo’s long-term profitability.</p><h2 class="st-heading-2"><strong>Stocktwits Users Debate Novo Nordisk’s Post-Earnings Dip</strong></h2><p>On Stocktwits, retail sentiment for Novo Nordisk was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img style="aspect-ratio:966/139;" src="https://news.stocktwits-cdn.com/nvo_ss_jpg_fe9afe78a9.webp" alt="nvo ss.jpg" width="966" height="139"><figcaption>NVO sentiment and message volume as of November 4 | Source: Stocktwits</figcaption></figure><p>One user said approval of Novo Nordisk’s GLP-1 pill in the U.S., combined with its recent acquisitions, could “make this stock explode,” predicting that the post-earnings dip would be quickly bought once European markets opened.</p><p><stembedurl>https://stocktwits.com/GetRektDoggy/message/634975033</stembedurl></p><p>Another user said the results amounted to a “small miss as expected,” noting that guidance had merely narrowed and speculated&nbsp;on the market’s move ahead of the Trump deal.</p><p><stembedurl>https://stocktwits.com/NorthstarT1D/message/634973987</stembedurl></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Novo Nordisk Q3 earnings and revenue climbed by double-digit percentages.

Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap?

Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

MTSR
Metsera Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MTSR News

MTSRMetsera Inc